$111.23
-0.08 (-0.07%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MANE is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional
Held by 10 tracked-famous managers (CITADEL ADVISORS LLC, VIKING GLOBAL INVESTORS LP, D. E. Shaw & Co., Inc., MAVERICK CAPITAL LTD, MARSHALL WACE, LLP, +5 more) · FINRA short interest 6.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)NCT07146022Changes in non-vellus Target Area Hair Counts (TAHC)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: VDPHL01 QD, Placebo, VDPHL01 BID, Placebo | Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia, Hair Loss | 552 | Jun 2027 | ≤ 314 d | 2026-08-17 |
| Safety and Efficacy of VDPHL01 in Males With AGANCT06972264Changes in non-vellus Target Area Hair Counts (TAHC)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: VDPHL01, Placebo | Androgenetic Alopecia, AGA, Male Pattern Baldness | 480 | Dec 2026 | ≤ 133 d | 2026-02-12 |
| Safety and Efficacy of VDPHL01 in Males and Females With AGANCT06527365Changes in non-vellus Total Area Hair Count (TAHC)Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: VDPHL01 | Androgenetic Alopecia, AGA, Male Pattern Baldness | 70 | Aug 2026 | ≤ 11 d | 2025-11-06 |
| Efficacy and Safety of VDPHL01 in Males With AGANCT06724614Changes in non-vellus Target Area Hair Counts (TAHC)Randomized · Quadruple-masked · Treatment | Phase 2/3 | Active, not recruiting | Drug: VDPHL01, Placebo | Androgenetic Alopecia, AGA, Male Pattern Baldness | 480 | Feb 2026 | — | 2025-11-06 |
| Safety and Efficacy of VDMN-21 Patch in Subjects With Common WartsNCT05799157Proportion of subjects with complete clinical resolution of the Target Lesion at end of treatment periodRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: VDMN-21 Patch Low Dose, VDMN-21 Patch High Dose, Vehicle Patch | Verruca Vulgaris, Warts, Common Wart | 153 | 2025-02-25actual | — | 2025-05-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19